Clinical Study

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With Mgmt Promoter Hypermethylation

Posted Date: Sep 7, 2017

  • Investigator: Rekha Chaudhary
  • Co-Investigator: Rekha Chaudhary
  • Specialties: Hematology/Oncology, Oncology, Cancer, Neurology
  • Type of Study: Drug

The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6

Criteria:

To Be Eligible To Participate, Patients Must Have A Type Of Brain Tumor Called A Glioblastoma Multiforme (Gbm) And Have Completed The First Part Of Treatment With Radiation Combined With The Chemotherapy Drug Temozolomide (Tmz).

Keywords:

Cancer, Glioblastoma, Mgmt Promoter Hypermethylation, A071102, Brain Tumor

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.